Patent intelligence · US
US 12285435
Multivesicular liposome formulations of dexamethasone
Multivesicular liposome formulations of dexamethasone
Patent details — US 12285435
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 29, 2025
- Expiration
- Apr 24, 2045
- Applicant
- Pacira Pharmaceuticals, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K31/573, A61K9/127, A61K9/1277
Quick answer
US 12285435 (Multivesicular liposome formulations of dexamethasone) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Apr 29, 2025. Expires Apr 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Pacira Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/573, A61K9/127, A61K9/1277
More from Pacira Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12370142
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12364764
Sustained release thermosetting gels comprising sodium channel blockers and the methods of making same
granted -
US 12318483
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12296047
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12285419
Bupivacaine multivesicular liposome formulations and uses thereof
granted -
US 12280149
Manufacturing of bupivacaine multivesicular liposomes
granted -
US 12251472
Manufacturing of bupivacaine multivesicular liposomes
granted
Frequently asked questions
What is US patent 12285435?
US 12285435 (Multivesicular liposome formulations of dexamethasone) is held by Pacira Pharmaceuticals, Inc.. Status: granted. Granted Apr 29, 2025. Expires Apr 24, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12285435?
Pacira Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 57 pharmaceutical patents for this assignee.
When does US 12285435 expire?
Our index shows an expiration date of Apr 24, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.